huahaipharm(SH:600521)2024-07-04 10:35Financial Performance - The estimated net profit attributable to shareholders for the first half of 2024 is expected to be between 728 million and 785 million CNY, representing an increase of approximately 159.18 million to 216.18 million CNY, or a year-on-year growth of about 28% to 38%[3]. - The estimated net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 745 million and 810 million CNY, reflecting an increase of approximately 96.84 million to 161.84 million CNY, or a year-on-year growth of about 15% to 25%[3]. - The net profit for the same period last year was 568.82 million CNY, and the net profit after deducting non-recurring gains and losses was 648.16 million CNY[5]. Factors Contributing to Growth - The increase in net profit is attributed to the continuous introduction and gradual increase in sales of new products, effective market expansion, and improvements in sales team structure and global sales network[6]. - The company has enhanced its cost control capabilities and overall strength through lean management optimization and technological upgrades, contributing to significant revenue growth[6]. Earnings Forecast - The earnings forecast is based on preliminary estimates and has not been audited, with final figures to be disclosed in the official half-year report[7]. - There are no major uncertainties affecting the accuracy of this earnings forecast[7].